LEXEO Therapeutics Announces Strategic Investment from Sarepta Therapeutics to Support Development of LEXEO’s Cardiovascular Gene Therapies
28 août 2023 07h30 HE
|
LEXEO Therapeutics
NEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a...
LEXEO Therapeutics Announces FDA Clearance of IND for LX2020, an AAV-based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy
01 août 2023 07h30 HE
|
LEXEO Therapeutics
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) is a devastating genetic cardiac disease affecting approximately 60,000 individuals in the United States LX2020 preclinical studies demonstrated...
LEXEO Therapeutics Announces Completion of First Cohort and Dosing in Second Cohort in SUNRISE-FA, a Phase 1/2 Clinical Trial of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
13 juin 2023 07h30 HE
|
LEXEO Therapeutics
LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two cohorts, including myocardial protein expression and...
LEXEO Therapeutics Announces Data Presentations at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
02 mai 2023 07h30 HE
|
LEXEO Therapeutics
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing adeno-associated virus (AAV)-based gene therapy candidates for genetically...
LEXEO Therapeutics Appoints Micah Zajic as Chief Financial Officer and Paula H. J. Cholmondeley as Board of Directors Audit Committee Chair
05 janv. 2023 07h30 HE
|
LEXEO Therapeutics
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for...
LEXEO Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 07h30 HE
|
LEXEO Therapeutics
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for...
LEXEO Therapeutics Bolsters Cardiac Gene Therapy Leadership with New Executive Appointment and Formation of Scientific Advisory Board
02 nov. 2022 07h30 HE
|
LEXEO Therapeutics
Eric Adler, M.D., joins LEXEO as Chief Scientific Officer New Scientific Advisory Board comprised of molecular cardiology, cardiovascular imaging, cardiac gene-editing, and RNA biology experts NEW...
LEXEO Therapeutics to Present Clinical and Preclinical Data at Upcoming Scientific Conferences
27 oct. 2022 07h30 HE
|
LEXEO Therapeutics
- Presentations at the International Congress for Ataxia Research (ICAR) will feature LEXEO’s LX2006 gene therapy program for Friedreich’s ataxia (FA) cardiomyopathy - - A presentation at American...
LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission
18 oct. 2022 07h30 HE
|
LEXEO Therapeutics
– LX1004 is an adeno-associated virus (AAV) based gene therapy for the treatment of CLN2 Batten disease – – In a completed Phase 1/2 clinical trial, LX1004 demonstrated a favorable safety profile and...
LEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting
05 oct. 2022 07h30 HE
|
LEXEO Therapeutics
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for...